Short Interest in DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Declines By 22.8%

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) saw a large drop in short interest in December. As of December 31st, there was short interest totaling 4,093,770 shares, a drop of 22.8% from the December 15th total of 5,301,959 shares. Based on an average daily volume of 379,867 shares, the short-interest ratio is presently 10.8 days. Currently, 8.5% of the company’s stock are sold short. Currently, 8.5% of the company’s stock are sold short. Based on an average daily volume of 379,867 shares, the short-interest ratio is presently 10.8 days.

Analysts Set New Price Targets

DMAC has been the subject of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Wednesday, October 8th. Cantor Fitzgerald assumed coverage on DiaMedica Therapeutics in a research note on Friday, November 14th. They set an “overweight” rating for the company. Cowen began coverage on DiaMedica Therapeutics in a report on Thursday, October 30th. They set a “buy” rating for the company. Wall Street Zen lowered DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Finally, TD Cowen began coverage on DiaMedica Therapeutics in a research report on Thursday, October 30th. They set a “buy” rating on the stock. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, DiaMedica Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $12.33.

Insider Transactions at DiaMedica Therapeutics

In other DiaMedica Therapeutics news, major shareholder Jan Stahlberg purchased 73,099 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was acquired at an average price of $8.57 per share, for a total transaction of $626,458.43. Following the purchase, the insider owned 8,825,742 shares of the company’s stock, valued at $75,636,608.94. This trade represents a 0.84% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders have acquired 1,061,277 shares of company stock valued at $7,632,627. Company insiders own 7.30% of the company’s stock.

Institutional Investors Weigh In On DiaMedica Therapeutics

Hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. boosted its stake in DiaMedica Therapeutics by 76.7% in the first quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company’s stock valued at $462,000 after acquiring an additional 52,854 shares during the last quarter. Perigon Wealth Management LLC bought a new stake in shares of DiaMedica Therapeutics in the 2nd quarter worth approximately $207,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of DiaMedica Therapeutics in the 2nd quarter worth approximately $29,000. World Investment Advisors lifted its stake in DiaMedica Therapeutics by 24.7% in the second quarter. World Investment Advisors now owns 31,975 shares of the company’s stock valued at $125,000 after purchasing an additional 6,325 shares during the last quarter. Finally, Cooperman Leon G grew its holdings in DiaMedica Therapeutics by 98.2% during the third quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock valued at $22,463,000 after purchasing an additional 1,619,761 shares during the period. 10.12% of the stock is currently owned by institutional investors.

DiaMedica Therapeutics Stock Performance

NASDAQ:DMAC traded down $0.97 on Friday, hitting $7.57. The stock had a trading volume of 614,875 shares, compared to its average volume of 190,724. The stock has a market cap of $394.22 million, a P/E ratio of -10.66 and a beta of 1.15. DiaMedica Therapeutics has a 1 year low of $3.19 and a 1 year high of $10.42. The firm’s fifty day simple moving average is $8.11 and its two-hundred day simple moving average is $6.63.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Equities research analysts predict that DiaMedica Therapeutics will post -0.59 EPS for the current year.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.